General Information of Drug (ID: DM1TKG4)

Drug Name
RDEA3170 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hyperuricaemia 5C55.Y Phase 2 [1]
Cross-matching ID
PubChem CID
54767229
CAS Number
CAS 1352792-74-5
TTD Drug ID
DM1TKG4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lesinurad DMUR64T Hyperuricaemia 5C55.Y Approved [3]
URC102 DMY89BN Gout FA25 Phase 2 [4]
RDEA-684 DMNWYHD Gout FA25 Phase 2 [3]
Sulfonamide derivative 11 DMJBR86 N. A. N. A. Patented [5]
Cycloalkyl acid derivative 1 DMXMGSP N. A. N. A. Patented [5]
2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1 DMHYIAV N. A. N. A. Patented [5]
Tihoacetate derivative 1 DM6QHO0 N. A. N. A. Patented [5]
Cycloalkyl acid derivative 2 DM09LY3 N. A. N. A. Patented [5]
Succinamide derivative 1 DMTXDSG N. A. N. A. Patented [5]
Benzene sulfonamide derivative 16 DMATBZW N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Urate anion exchanger 1 (URAT1) TTA592U S22AC_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT02078219) Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia. U.S. National Institutes of Health.
2 The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
4 Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
5 Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.